Go online to PeerView.com/BUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView “How I Think, How I Treat” CME video activity, multiple myeloma (MM) experts explore the era of antibody-based therapy and the implications of new science for treatment decisions from early disease settings through the management of relapsed/refractory MM. By sharing their personal insights and intra-institutional experiences, and combining these reflections with in-depth analysis of recent evidence on anti-CD38, SLAMF7, and BCMA-targeting antibodies, Drs. Sagar Lonial and Robert Z. Orlowski recommend ways to improve clinical outcomes related to the integration of antibody therapy into modern MM management. Don’t miss this opportunity to get informed on the unique anticancer mechanisms of antibody-based therapy, as well as the safety and efficacy evidence supporting its use across the wide spectrum of MM presentations. Upon completion of this activity, participants should be better able to: Summarize the therapeutic targets and mechanisms associated with novel antibodies in multiple myeloma, including CD38, SLAMF7, and BCMA, among others, Discuss current efficacy and safety evidence surrounding the use of novel and next-generation antibodies in patients with newly diagnosed or relapsed/refractory multiple myeloma, Develop personalized treatment regimens with novel antibody components for patients with newly diagnosed or relapsed/refractory multiple myeloma, Manage practical considerations related to the use of antibody-based regimens in multiple myeloma, including unique adverse events, dosing considerations, and interference with blood compatibility testing, among others.
Podden och tillhörande omslagsbild på den här sidan tillhör PVI, PeerView Institute for Medical Education. Innehållet i podden är skapat av PVI, PeerView Institute for Medical Education och inte av, eller tillsammans med, Poddtoppen.